CY1116513T1 - Piperidinone Derivatives as MDM2 Inhibitors for Cancer Therapeutic Treatment - Google Patents

Piperidinone Derivatives as MDM2 Inhibitors for Cancer Therapeutic Treatment

Info

Publication number
CY1116513T1
CY1116513T1 CY20151100635T CY151100635T CY1116513T1 CY 1116513 T1 CY1116513 T1 CY 1116513T1 CY 20151100635 T CY20151100635 T CY 20151100635T CY 151100635 T CY151100635 T CY 151100635T CY 1116513 T1 CY1116513 T1 CY 1116513T1
Authority
CY
Cyprus
Prior art keywords
therapeutic treatment
cancer therapeutic
mdm2 inhibitors
piperidinone derivatives
piperidinone
Prior art date
Application number
CY20151100635T
Other languages
Greek (el)
Inventor
Michael David Bartberger
Buenrostro Ana Gonzalez
Hilary Plake Beck
Xiaoqi Chen
Richard Victor Connors
Jeffrey Deignan
Jason Duquette
John Eksterowicz
Benjamin Fisher
Brian Matthew Fox
Jiasheng Fu
Zice Fu
Lopez De Turiso Felix Gonzalez
Jr Michael William Gribble
Darin James Gustin
Julie Anne Heath
Xin Huang
Xianyun Jiao
Michael Johnson
Frank Kayser
David John Kopecky
Sujen Lai
Yihong Li
Zhihong Li
Jiwen Liu
Jonathan Dante Low
Brian Stuart Lucas
Zhihua Ma
Lawrence Mcgee
Joel Mcintosh
Dustin Mcminn
Julio Cesar Medina
Jeffrey Thomas Mihalic
Steven Howard Olson
Yosup Rew
Philip Marley Roveto
Daqing Sun
Xiaodong Wang
Yingcai Wang
Xuelei Yan
Ming Yu
Jiang Zhu
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20110726581 external-priority patent/EP2576510B1/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1116513T1 publication Critical patent/CY1116513T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις αναστολέων της MDM2 Τύπου (I), με τις σχετικές μεταβλητές να ορίζονται πιο πάνω, οι οποίες ενώσεις είναι χρήσιμες ως θεραπευτικοί παράγοντες, συγκεκριμένα για τη θεραπευτική αγωγή καρκίνων. Η παρούσα εφεύρεση σχετίζεται επίσης με φαρμακευτικές συνθέσεις που περιέχουν αναστολέα της MDM2.The present invention provides MDM2 inhibitor compounds of Formula (I), with the relevant variables defined above, which compounds are useful as therapeutic agents, in particular for the treatment of cancers. The present invention also relates to pharmaceutical compositions containing MDM2 inhibitor.

CY20151100635T 2010-06-04 2015-07-17 Piperidinone Derivatives as MDM2 Inhibitors for Cancer Therapeutic Treatment CY1116513T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35182710A 2010-06-04 2010-06-04
US35232210A 2010-06-07 2010-06-07
US201161452578P 2011-03-14 2011-03-14
EP20110726581 EP2576510B1 (en) 2010-06-04 2011-06-03 Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1116513T1 true CY1116513T1 (en) 2017-03-15

Family

ID=58459759

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100635T CY1116513T1 (en) 2010-06-04 2015-07-17 Piperidinone Derivatives as MDM2 Inhibitors for Cancer Therapeutic Treatment

Country Status (1)

Country Link
CY (1) CY1116513T1 (en)

Similar Documents

Publication Publication Date Title
CY1121265T1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
CY1123626T1 (en) HETEROCYCLIC PROTEIN KINASE INHIBITORS
CY1119387T1 (en) TRIAZOLOPYRAZINS AS BRD4 INHIBITORS FOR USE IN CANCER TREATMENT
CY1122611T1 (en) PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
MX2015012427A (en) Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer.
MX352672B (en) Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer.
CY1119056T1 (en) 2 ', 4', - DIFFluoro-2'-Methyl-Substituted Nucleoside Derivatization as HCV RNA Replication Inhibitors
EA201590879A1 (en) ARYL-CONDENSED AND HETEROARYL-CONDENSED LACTAMS
CO6321282A2 (en) PIPERIDINYLINDOL DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
CR20110028A (en) PIRIMIDINE DERIVATIVES AS CINASE INHIBITORS
EA201590284A1 (en) DIHYDROPYRIDON R1 AS INHIBITOR FACTOR XIA
EA201590277A1 (en) DIHYDROPYRIDON R1 AS INHIBITOR FACTOR XIA
MX2012000711A (en) Pyrrolopyrazine inhibitors of kinases.
CR20120641A (en) MACROCYCLICAL COMPOUNDS AS QUINASA TRK INHIBITORS
CY1112465T1 (en) AMINOTRIAZOL PRODUCTS AS ALX AGONISTS
CO6362015A2 (en) 1-AMINO-2CICLOBUTILETILBORONIC ACID DERIVATIVES
BR112012010186B8 (en) heteroaryl derivatives containing n as jak3 kinase inhibitors and pharmaceutical composition comprising them
EA201291217A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES 1- (β-D-GLUKOPIRANOSIL) -2-THIENYLMETYLBENZENE AS NZGT INHIBITORS
CY1120378T1 (en) Substituted Derivatized Butane Phosphonic Acid Binding Derivatives as Water Inhibitors
MX362896B (en) Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer.
MX360330B (en) Administration regime for nitrocatechols.
CY1120133T1 (en) Pyridazines as DAAO Enzyme Inhibitors
EA201170997A1 (en) INDOL DERIVATIVES AS ANTI-TREATMENT AGENTS
EA201270302A1 (en) ANHARROUND FORMS OF PYRIDINE DERIVATIVES
UY31775A (en) HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS